NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Therapeutics announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 3,000,000 ordinary shares in a registered direct offering and ordinary warrants to purchase up to 3,000,000 ordinary shares in a concurrent private placement at a combined purchase price of $1.50.